T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TPH
1676
DELISTED
Tri Pointe Homes
TPH
| $1.2M | ﹤0.01% |
76,100
| – | – |
|
1677
Bank of Montreal
BMO
$130B
| $1.19M | ﹤0.01% |
16,100
+11,996
| +292% | +$836K |
|
|
WCC
1678
WESCO International
WCC
$17.6B
| $1.19M | ﹤0.01% |
13,751
| – | – |
|
|
SRC
1679
DELISTED
SPIRIT REALTY CAPITAL, INC.
SRC
| $1.19M | ﹤0.01% |
23,326
+1,494
| +7% | +$74.2K |
|
|
TGI
1680
DELISTED
Triumph Group
TGI
| $1.19M | ﹤0.01% |
17,000
-16,200
| -49% | -$1.09M |
|
|
TECD
1681
DELISTED
Tech Data Corp
TECD
| $1.19M | ﹤0.01% |
18,980
+2,000
| +12% | +$124K |
|
|
STR
1682
DELISTED
QUESTAR CORP
STR
| $1.17M | ﹤0.01% |
47,300
+1,600
| +4% | +$38K |
|
|
DRC
1683
DELISTED
DRESSER-RAND GROUP INC
DRC
| $1.17M | ﹤0.01% |
18,400
+1,200
| +7% | +$73.2K |
|
|
DFRG
1684
DELISTED
Del Frisco's Restaurant Group, Inc. Common Stock
DFRG
| $1.17M | ﹤0.01% |
42,500
+29,900
| +237% | +$797K |
|
|
OPLN
1685
Openlane
OPLN
$4.38B
| $1.16M | ﹤0.01% |
95,780
+10,565
| +12% | +$122K |
|
1686
Hyatt Hotels
H
$17B
| $1.15M | ﹤0.01% |
18,800
-5,400
| -22% | -$311K |
|
1687
Lamar Advertising Co
LAMR
$15.8B
| $1.14M | ﹤0.01% |
21,592
+1,400
| +7% | +$70.7K |
|
1688
WaFd
WAFD
$2.8B
| $1.14M | ﹤0.01% |
51,010
+19,200
| +60% | +$420K |
|
1689
Advanced Micro Devices
AMD
$829B
| $1.14M | ﹤0.01% |
272,687
-813
| -0.3% | -$3.29K |
|
1690
SAP
SAP
$241B
| $1.14M | ﹤0.01% |
14,800
| – | – |
|
1691
NNN REIT
NNN
$8.88B
| $1.14M | ﹤0.01% |
30,530
-2,790
| -8% | -$98.1K |
|
|
PNY
1692
DELISTED
PIEDMONT NATURAL GAS CO INC(NC
PNY
| $1.13M | ﹤0.01% |
30,300
+4,100
| +16% | +$147K |
|
1693
Avista
AVA
$3.28B
| $1.13M | ﹤0.01% |
33,790
-3,900
| -10% | -$123K |
|
|
DBD
1694
DELISTED
Diebold Nixdorf Incorporated
DBD
| $1.13M | ﹤0.01% |
28,190
| – | – |
|
1695
United Natural Foods
UNFI
$2.91B
| $1.11M | ﹤0.01% |
17,000
-1,700
| -9% | -$114K |
|
1696
Invesco Mortgage Capital
IVR
$804M
| $1.1M | ﹤0.01% |
6,350
+1,280
| +25% | +$219K |
|
|
UPL
1697
DELISTED
Ultra Petroleum Corp. Common Stock
UPL
| $1.1M | ﹤0.01% |
36,960
| – | – |
|
|
HNT
1698
DELISTED
HEALTH NET INC
HNT
| $1.09M | ﹤0.01% |
26,330
+2,000
| +8% | +$74.5K |
|
|
BRSL
1699
Brightstar Lottery PLC
BRSL
$2.17B
| $1.09M | ﹤0.01% |
68,500
-321,018
| -82% | -$4.35M |
|
1700
Delek US
DK
$4.02B
| $1.09M | ﹤0.01% |
38,500
-151,200
| -80% | -$4.65M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.